Article
Medicine, General & Internal
Satoshi Ikeda, Akimasa Sekine, Tomohisa Baba, Terufumi Kato, Takuma Katano, Erina Tabata, Ryota Shintani, Hideaki Yamakawa, Tsuneyuki Oda, Ryo Okuda, Hideya Kitamura, Tae Iwasawa, Tamiko Takemura, Takashi Ogura
Summary: This study compared the efficacy and safety of nintedanib with or without pirfenidone for patients with idiopathic pulmonary fibrosis (IPF) who experienced disease progression during previous pirfenidone therapy. Results showed that the combination group had a higher incidence of forced vital capacity (FVC) decline during the first 6 months compared to the switch group.
Review
Respiratory System
Steven D. Nathan, Jack Wanger, Joseph D. Zibrak, Mark L. Wencel, Cindy Burg, John L. Stauffer
Summary: FVC decline in the clinic plays a critical role in monitoring disease progression in patients with IPF, but additional measures should be considered to facilitate decision-making about disease management. Home spirometry devices may offer potential for more frequent and accurate data collection.
EXPERT REVIEW OF RESPIRATORY MEDICINE
(2021)
Article
Chemistry, Multidisciplinary
S. Park, J. Y. Park, J. H. Nahm, G. Kim, Y. L. Cho, W. J. Kang, J. Key
Summary: This study prepared nintedanib-loaded poly (lactic-co-glycolic acid)-based discoidal polymeric particles (Nib-PLGA-DPPs) for the treatment of idiopathic pulmonary fibrosis (IPF). The Nib-PLGA-DPPs showed improved therapeutic efficacy in reducing fibrosis and inflammation compared to nintedanib alone.
MATERIALS TODAY CHEMISTRY
(2022)
Article
Biochemistry & Molecular Biology
Paolo Cameli, Valerio Alonzi, Miriana d'Alessandro, Laura Bergantini, Elena Pordon, Marco Guerrieri, Rosa Metella Refini, Piersante Sestini, Elena Bargagli
Summary: This study aimed to investigate the effectiveness and safety of nintedanib in reducing functional disease progression in patients with IPF and PF-ILD. The results showed that nintedanib significantly reduced the decline rate of FVC in IPF and PF-ILD patients, but had no significant impact on FPF patients. Survival analysis revealed that gender and impaired lung function influenced the survival of patients.
Article
Respiratory System
Manon Belhassen, Faustine Dalon, Maeva Nolin, Eric Van Ganse
Summary: This study using data from the French National Health System evaluated outcomes in IPF patients newly treated with pirfenidone or nintedanib in 2015-2016. Results showed that compared to pirfenidone, nintedanib treatment was associated with a higher risk of all-cause mortality, acute respiratory-related hospitalisations, and a lower risk of treatment discontinuation at 12 months.
RESPIRATORY RESEARCH
(2021)
Article
Cell Biology
Kazutaka Takehara, Yasuhiko Koga, Yoshimasa Hachisu, Mitsuyoshi Utsugi, Yuri Sawada, Yasuyuki Saito, Seishi Yoshimi, Masakiyo Yatomi, Yuki Shin, Ikuo Wakamatsu, Kazue Umetsu, Shunichi Kouno, Junichi Nakagawa, Noriaki Sunaga, Toshitaka Maeno, Takeshi Hisada
Summary: In patients with IPF, the discontinuation rate of nintedanib treatment due to adverse events is higher than that of pirfenidone treatment. Better management of adverse events with nintedanib leads to more continuous treatment, preventing disease progression and acute exacerbations, thus improving prognosis for IPF patients.
Article
Medicine, General & Internal
Donato Lacedonia, Michele Correale, Lucia Tricarico, Giulia Scioscia, Silvia Romana Stornelli, Filomena Simone, Massimo Casparrini, Natale Daniele Brunetti, Maria Pia Foschino Barbaro
Summary: IPF is a chronic progressive disease that leads to respiratory failure and death within years, particularly poor in patients with PH. Severity of PH is associated with reduction of DLCO value and increase of the GAP index. Echocardiographic stratification may be useful in predicting prognosis and determining specific treatments.
INTERNAL AND EMERGENCY MEDICINE
(2022)
Review
Biochemistry & Molecular Biology
Francesco Amati, Anna Stainer, Veronica Polelli, Marco Mantero, Andrea Gramegna, Francesco Blasi, Stefano Aliberti
Summary: Pirfenidone and nintedanib are effective in slowing disease progression in interstitial lung diseases other than idiopathic pulmonary fibrosis. Two well-designed trials demonstrate the efficacy of nintedanib, while caution should be taken in interpreting the results of pirfenidone due to trial limitations. Ongoing randomized control trials aim to improve the quality of evidence in this field.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Respiratory System
Yoshikazu Inoue, Athol U. Wells, Jin Woo Song, Zuojun Xu, Hideya Kitamura, Takafumi Suda, Masaki Okamoto, Heiko Mueller, Carl Coeck, Klaus B. Rohr, Martin Kolb, Kevin K. Brown
Summary: In the INBUILD trial, nintedanib was found to slow down the decline in forced vital capacity in Asian patients with progressive fibrosing ILDs, although some patients experienced gastrointestinal adverse events.
Article
Respiratory System
Timothy M. Dempsey, Stephanie Payne, Lindsey Sangaralingham, Xiaoxi Yao, Nilay D. Shah, Andrew H. Limper
Summary: Since their approval in 2014, the adoption of pirfenidone and nintedanib in the United States has been low, which may be associated with the high out-of-pocket costs.
ANNALS OF THE AMERICAN THORACIC SOCIETY
(2021)
Article
Medicine, General & Internal
Cheng-Yu Chang, Yu-Feng Wei, Chung-Yu Chen, Yi-Chun Lai, Po-Wei Hu, Jui-Chi Hung, Chi-Hsiang Chu, Hsin-Tzu Chuang, Shih-Chieh Chang
Summary: This study in Taiwan investigated the real-world effectiveness and safety profile of pirfenidone treatment for patients with idiopathic pulmonary fibrosis over a 12-month period. The results showed that the drug preserved lung function, improved quality of life, and had tolerable side effects such as gastrointestinal upset and dermatological problems.
FRONTIERS IN MEDICINE
(2023)
Article
Respiratory System
Pavo Marijic, Larissa Schwarzkopf, Lars Schwettmann, Thomas Ruhnke, Franziska Trudzinski, Michael Kreuter
Summary: This study compared patients treated with pirfenidone and nintedanib in terms of mortality, hospitalization, and healthcare costs, finding no significant differences between the two drugs in these patient-related outcomes.
RESPIRATORY RESEARCH
(2021)
Article
Respiratory System
Megan L. Neely, Anne S. Hellkamp, Shaun Bender, Jamie L. Todd, Timothy Liesching, Tracy R. Luckhardt, Justin M. Oldham, Rishi Raj, Eric S. White, Scott M. Palmer
Summary: This study evaluated the trajectories of lung function decline in patients with IPF and found that IPF is characterized by a progressive decline in lung function. Male, white, patients with a family history of ILD, oxygen users, and those using antifibrotic therapy had a greater decline in lung function.
RESPIRATORY RESEARCH
(2023)
Article
Chemistry, Medicinal
Motoyasu Kato, Shinichi Sasaki, Misa Tateyama, Yuta Arai, Hiroaki Motomura, Issei Sumiyoshi, Yusuke Ochi, Junko Watanabe, Hiroaki Ihara, Shinsaku Togo, Kazuhisa Takahashi
Summary: The study showed that poor performance status can lead to discontinuation of nintedanib treatment after 12 months, but long-term nintedanib treatment may be beneficial for patient survival.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Medical Informatics
Hernan P. Fainberg, Justin M. Oldham, Philip L. Molyneaux, Richard J. Allen, Luke M. Kraven, William A. Fahy, Joanne Porte, Rebecca Braybrooke, Gauri Saini, Morten A. Karsdal, Diane J. Leeming, Jannie M. B. Sand, Isaac Triguero, Eunice Oballa, Athol U. Wells, Elisabetta Renzoni, Louise Wain, Imre Noth, Toby M. Maher, Iain D. Stewart, R. Gisli Jenkins
Summary: In this study, we used machine learning techniques to identify distinct clusters of lung function trajectory in patients with idiopathic pulmonary fibrosis. The results revealed four clusters with different clinical and biochemical features. Stratifying spirometric data into these clusters may improve the evaluation of intervention efficacy in clinical trials and patient management.
LANCET DIGITAL HEALTH
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Junya Tominaga, Alexander A. Bankier, Kyung Soo Lee, Ann N. Leung, Martine Remy-Jardin, Masanori Akira, Hiroaki Arakawa, Phillip M. Boiselle, Tomas Franquet, Kiminori Fujimoto, Pierre Alain Gevenois, Jin Mo Goo, Philippe A. Grenier, Hiroto Hatabu, Kazuya Ichikado, Jung-Gi Im, Takeshi Johkoh, Ki-Nam Lee, David A. Lynch, Satoshi Noma, Jae-Woo Song, Fumikazu Sakai, Yukihiko Sugiyama
JAPANESE JOURNAL OF RADIOLOGY
(2019)
Article
Cardiac & Cardiovascular Systems
Luca Richeldi, Bruno Crestani, Arata Azuma, Martin Kolb, Moises Selman, Wibke Stansen, Manuel Quaresma, Susanne Stowasser, Vincent Cottin
RESPIRATORY MEDICINE
(2019)
Article
Genetics & Heredity
Naoto Keicho, Minako Hijikata, Kozo Morimoto, Sakae Homma, Yoshio Taguchi, Arata Azuma, Shoji Kudoh
MOLECULAR GENETICS & GENOMIC MEDICINE
(2020)
Article
Critical Care Medicine
Yasuhiro Kondoh, Arata Azuma, Yoshikazu Inoue, Takashi Ogura, Susumu Sakamoto, Kenji Tsushima, Takeshi Johkoh, Kiminori Fujimoto, Kazuya Ichikado, Yasuo Matsuzawa, Takefumi Saito, Kazuma Kishi, Keisuke Tomii, Noriho Sakamoto, Masahiro Aoshima, Jun Araya, Shinyu Izumi, Machiko Arita, Mitsuhiro Abe, Hiroyoshi Yamauchi, Joe Shindoh, Takafumi Suda, Masaki Okamoto, Masahito Ebina, Yoshihito Yamada, Yuji Tohda, Tetsuji Kawamura, Yoshio Taguchi, Hiroshi Ishii, Naozumi Hashimoto, Shinji Abe, Hiroyuki Taniguchi, Jun Tagawa, Koji Bessho, Natsuki Yamamori, Sakae Homma
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2020)
Review
Rheumatology
Masataka Kuwana, Arata Azuma
MODERN RHEUMATOLOGY
(2020)
Letter
Critical Care Medicine
Yasuhiro Kondoh, Arata Azuma, Jun Tagawa, Sakae Homma
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2020)
Letter
Critical Care Medicine
Yasuhiro Kondoh, Arata Azuma, Jun Tagawa, Natsuki Yamamori, Sakae Homma
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2020)
Letter
Critical Care Medicine
Nadera J. Sweiss, Peter Korsten, Huzaefah J. Syed, Aamer Syed, Robert P. Baughman, Arthur M. F. Yee, Daniel A. Culver, Teresa Sosenko, Arata Azuma, Francesco Bonella, Ulrich Costabel, Wonder P. Drake, Marjolein Drent, Elyse E. Lower, Dominique Israel-Biet, Remy L. M. Mostard, Hilario Nunes, Paola Rottoli, Paolo Spagnolo, Athol U. Wells, Wim A. Wuyts, Marc A. Judson
Article
Cardiac & Cardiovascular Systems
Kenji Yodogawa, Yoshimitsu Fukushima, Takahiro Ando, Yu-ki Iwasaki, Kazuyoshi Akiyama, Shin-ichiro Kumita, Arata Azuma, Yoshihiko Seino, Wataru Shimizu
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2020)
Article
Rheumatology
Masataka Kuwana, Takashi Ogura, Shigeki Makino, Sakae Homma, Yasuhiro Kondoh, Aiko Saito, Hiroyuki Ugai, Martina Gahlemann, Kazuhiko Takehara, Arata Azuma
Summary: Nintedanib demonstrated efficacy in Japanese patients with SSc-ILD, showing a slower decline in FVC compared to placebo over 52 weeks. There was no heterogeneity detected in treatment effect between Japanese and non-Japanese patients, and the safety profile of nintedanib in Japanese patients was similar to that in patients with idiopathic pulmonary fibrosis.
MODERN RHEUMATOLOGY
(2021)
Editorial Material
Respiratory System
Yasuo Morimoto, Hena Khatun, Kwok Sang Wilson Yee, Agus Dwi Susanto, Jun-Pyo Myong, Joven Jeremius Tanchuco, Chau-Chyun Sheu, Ngo Quy Chau, Arata Azuma
Article
Rheumatology
James R. Seibold, Toby M. Maher, Kristin B. Highland, Shervin Assassi, Arata Azuma, Laura Kathleen Hummers, Ulrich Costabel, Ute von Wangenheim, Veronika Kohlbrenner, Martina Gahlemann, Margarida Alves, Oliver Distler
ANNALS OF THE RHEUMATIC DISEASES
(2020)
Article
Medicine, General & Internal
Naoyuki Kuse, Koichiro Kamio, Arata Azuma, Kuniko Matsuda, Minoru Inomata, Jiro Usuki, Akemi Morinaga, Toru Tanaka, Takeru Kashiwada, Kenichiro Atsumi, Hiroki Hayashi, Yoshinobu Saito, Masahiro Seike, Akihiko Gemma
JOURNAL OF NIPPON MEDICAL SCHOOL
(2020)
Review
Respiratory System
Arata Azuma, Luca Richeldi
TUBERCULOSIS AND RESPIRATORY DISEASES
(2020)
Article
Respiratory System
Yuji Minegishi, Akihiko Gemma, Sakae Homma, Kazuma Kishi, Arata Azuma, Takashi Ogura, Naoki Hamada, Hiroyuki Taniguchi, Noboru Hattori, Yasuhiko Nishioka, Kiminobu Tanizawa, Takeshi Johkoh, Takuma Yokoyama, Kazutaka Mori, Yoshio Taguchi, Masahito Ebina, Naohiko Inase, Koichi Hagiwara, Hiroshi Ohnishi, Hiroshi Mukae, Yoshikazu Inoue, Kazuyoshi Kuwano, Hirofumi Chiba, Ken Ohta, Yoshinori Tanino, Fumikazu Sakai, Yukihiko Sugiyama